Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-cash Items (2018 - 2024)

Zevra Therapeutics' Non-cash Items history spans 9 years, with the latest figure at $2.4 million for Q4 2024.

  • For Q4 2024, Non-cash Items fell 78.36% year-over-year to $2.4 million; the TTM value through Dec 2024 reached $2.4 million, down 78.36%, while the annual FY2024 figure was $2.4 million, 78.36% down from the prior year.
  • Non-cash Items reached $2.4 million in Q4 2024 per ZVRA's latest filing, down from $11.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $11.8 million in Q4 2022 to a low of $254207.0 in Q4 2021.
  • Average Non-cash Items over 5 years is $5.2 million, with a median of $2.4 million recorded in 2024.
  • Peak YoY movement for Non-cash Items: surged 4549.36% in 2022, then plummeted 78.36% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $543021.0 in 2020, then tumbled by 53.19% to $254207.0 in 2021, then soared by 4549.36% to $11.8 million in 2022, then fell by 6.18% to $11.1 million in 2023, then tumbled by 78.36% to $2.4 million in 2024.
  • Per Business Quant, the three most recent readings for ZVRA's Non-cash Items are $2.4 million (Q4 2024), $11.1 million (Q4 2023), and $11.8 million (Q4 2022).